However, pharmacogenetic testing for the TPMT alleles *2 (rs1800462), *3A (rs1800460 and rs1142345), *3B (rs1800460) or *3C (rs1142345) is recommended by the Canadian Pharmacogenomics Network for Drug Safety in pediatric cancer patients when prescribing cisplatin (PharmGKB ID PA166170751). This evidence concerns the gene TPMT and cancer.